Zokinvy is owned by Eiger Biopharms.
Zokinvy contains Lonafarnib.
Zokinvy has a total of 2 drug patents out of which 0 drug patents have expired.
Zokinvy was authorised for market use on 20 November, 2020.
Zokinvy is available in capsule;oral dosage forms.
Zokinvy can be used as reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps).
Drug patent challenges can be filed against Zokinvy from November, 2024.
The generics of Zokinvy are possible to be released after 20 November, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8828356||EIGER BIOPHARMS||Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis|| |
(8 months from now)
|US7838531||EIGER BIOPHARMS||Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis|| |
(1 year, 5 months from now)
|Orphan Drug Exclusivity (ODE)||Nov 20, 2027|
|New Chemical Entity Exclusivity (NCE)||Nov 20, 2025|
NCE-1 date: November, 2024
Market Authorisation Date: 20 November, 2020
Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic